Oncology Institute (DFPH) Gross Profit (2021 - 2026)

Oncology Institute (DFPH) has 6 years of Gross Profit data on file, last reported at $139.2 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 90.65% year-over-year to $139.2 million; the trailing twelve-month figure through Mar 2026 stood at $470.9 million (up 19.05% YoY), and the FY2025 full-year result was $282.2 million, down 28.04% from the prior year.
• Gross Profit for Q1 2026 stood at $139.2 million, up from $75.4 million in the prior quarter.
• Across five years, Gross Profit topped out at $210.7 million in Q4 2024 and bottomed at $27.8 million in Q1 2022.
• The 5-year median for Gross Profit is $60.8 million (2022), against an average of $74.1 million.
• The widest annual swing landed in 2024, when Gross Profit surged 462.91%; it then slumped 64.2% in 2025.
• A 5-year view of Gross Profit shows it stood at $71.3 million in 2022, then sank by 47.52% to $37.4 million in 2023, then soared by 462.91% to $210.7 million in 2024, then plunged by 64.2% to $75.4 million in 2025, then jumped by 84.52% to $139.2 million in 2026.
• The last three Gross Profit figures came in at $139.2 million (Q1 2026), $75.4 million (Q4 2025), and $136.6 million (Q3 2025), per Business Quant data.

Peer Comparison